Investing.com – Biogen (NASDAQ:) reported on Thursday first quarter that beat analysts’ forecasts and revenue that topped expectations.
Biogen announced earnings per share of $5.34 on revenue of $2.69B. Analysts polled by Investing.com anticipated EPS of $5.02 on revenue of $2.66B.
Biogen shares are up 10% from the beginning of the year, still down 25.85% from its 52 week high of $363.92 set on November 4, 2020. They are outperforming the Nasdaq which is up 8.24% from the start of the year.
Biogen follows other major Healthcare sector earnings this month
Biogen’s report follows an earnings beat by J&J on Tuesday, who reported EPS of $2.59 on revenue of $22.32B, compared to forecasts EPS of $2.33 on revenue of $22.01B.
Abbott Labs had beat expectations on Tuesday with first quarter EPS of $1.32 on revenue of $10.46B, compared to forecast for EPS of $1.27 on revenue of $10.69B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Need Your Help Today. Your $1 can change life.